← Back

MiMedx Group Inc

MiMedx Group, Inc. develops and distributes placental tissue allografts for various healthcare sectors. Using its patented and proprietary PURION process, the company processes human placental tissue membrane, umbilical cord, and placental disc to produce allografts that retain the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its processing method employs aseptic techniques along with terminal sterilization. Wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets, which serve as protective barriers and allow providers to select a graft size matching the wound to reduce product waste. Surgical and other offerings include AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications such as lower extremity repair, plastic surgery, vascular surgery, and orthopedic repairs and reconstructions. Products are used in wound care, burn, and surgical fields. The company sells through a direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States, and has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. MiMedx was founded in 2006 and is headquartered in Marietta, Georgia.

Price · split & dividend adjusted
News & notes moving MDXG
United States
MDXG▲

Monteverde & Associates investigates four mergers for potential shareholder claims

Monteverde & Associates PC is investigating four proposed acquisitions for potential breaches of fiduciary duty and other violations of law. The firm is examining the sale of Forte Biosciences to argenx BV at $77.00 per share in cash, Luxfer Holdings to affiliates of Wynnchurch Capital at $17.37 per share in cash, Sanara MedTech to MiMedx Group for $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, and MarketAxess Holdings to Intercontinental Exchange at $167.00 per share in cash. Shareholders are encouraged to contact the firm before the applicable tender offer deadlines, including August 26, 2026 for Forte Biosciences.
FBRX ▲ICE ▲LXFR ▲MDXG ▲MKTX ▲SMTI
FBRX · Capital · Positive Acquisition at $77.00 per share in cash, a premium for shareholders.
ICE · Capital · Positive Acquiring MarketAxess at $167.00 per share in cash, expanding ICE's business.
LXFR · Capital · Positive Acquisition at $17.37 per share in cash, providing value to shareholders.
MDXG · Capital · Positive Acquiring Sanara MedTech with cash and stock, strategic expansion.
MKTX · Capital · Positive Being acquired at $167.00 per share in cash, a premium for shareholders.
SMTI · Capital · Neutral Acquisition by MiMedx at $33 cash plus shares; investigation into potential fiduciary breaches may affect deal terms.
Read original ↗
GlobeNewswire·59dRead more →
Biotech & Genomic Medicine▲

SciSparc, Avantor, NeoGenomics Lead Biotech Gains on Milestones and Upgraded Outlooks

Several biotech stocks posted sharp gains on Wednesday, led by SciSparc after its subsidiary completed internal validation of a quantum sampling platform for clinical trial data. SciSparc closed at $9.09, up 70.54%, following the announcement that NeuroThera Labs successfully validated the platform being advanced by CliniQuantum, in which NeuroThera holds a 54.01% ownership interest. Avantor rose 15.78% to $14.38 after reporting second-quarter net sales of $1.69 billion and raising its full-year adjusted EPS guidance to $0.80 to $0.83 from $0.77 to $0.83. NeoGenomics gained 13.96% to $15.27 after second-quarter consolidated revenue increased 11% to $202 million and the company lifted its full-year revenue outlook to $802 million to $806 million from $797 million to $803 million. Alvotech climbed 13.87% to $3.53 after the FDA classified the inspection of its Reykjavik manufacturing facility as Voluntary Action Indicated, a step forward for its biosimilar applications. Sanara MedTech surged 13.55% to $30.25 after agreeing to be acquired by MiMedx Group in a cash-and-stock deal valued at $35 per share, or about $350 million in total enterprise value. LB Pharmaceuticals advanced 11.62% to $39.00 after securing a $150 million private placement and accelerating the timeline for topline results from its Phase 3 schizophrenia trial to the first half of 2027.
ALVO ▲AVTR ▲LBRX ▲MDXG ▲NEO ▲SMTI ▲+1
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › CDMO / Contract Manufacturing ▲Regulation
Biotech & Genomic Medicine › Biosimilars ▲Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Demand
ALVO · Regulation · Positive FDA classified inspection as Voluntary Action Indicated, a step forward for biosimilar applications.
AVTR · Capital · Positive Reported Q2 net sales of $1.69B and raised full-year adjusted EPS guidance.
LBRX · Capital · Positive Secured $150M private placement and accelerated Phase 3 schizophrenia trial timeline.
MDXG · Capital · Positive Agreed to acquire Sanara MedTech in a cash-and-stock deal valued at $35 per share.
NEO · Capital · Positive Q2 consolidated revenue increased 11% to $202M and lifted full-year revenue outlook.
SMTI · Capital · Positive Sanara MedTech agreed to be acquired by MiMedx Group at $35 per share, a premium to its prior price.
Read original ↗
RTTNews·66dRead more →
MDXG▼

MIMEDX Reports Second Quarter Net Sales of $64 Million and Plans to Acquire Sanara MedTech

MIMEDX announced second quarter 2026 net sales of $64 million, a 35% decline from the prior year, and separately unveiled a definitive agreement to acquire Sanara MedTech in a cash-and-stock deal valued at approximately $350 million. Surgical product sales grew 15% year-over-year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes that took effect on January 1. The company reported a net loss of $15 million for the quarter, compared to net income of $10 million a year earlier, and held $136 million in cash and equivalents as of June 30. MIMEDX reiterated its full-year 2026 net sales guidance of $260 to $290 million and expects Adjusted EBITDA to approach breakeven. Under the Sanara acquisition terms, Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MIMEDX common stock per share, representing a 46% premium to Sanara’s 30-day volume-weighted average price, with the transaction expected to close by year-end subject to shareholder and regulatory approvals.
MDXG ▼SMTI ▲
MDXG · Capital · Negative Net sales fell 35% and net loss of $15 million vs prior year profit.
SMTI · Capital · Positive Acquisition at 46% premium to 30-day VWAP.
Read original ↗
GlobeNewswire·67dRead more →
Biotech & Genomic Medicine▼

Regenerative Medicine Market Projected to Surpass $100 Billion Within a Decade

The regenerative medicine market is projected to surpass US$100 billion within roughly a decade, driven by a shift from tissue replacement to regeneration using biomaterials, cell therapies, and 3D bioprinting. Independent estimates place the broad market in the tens of billions of dollars in 2026, with compound annual growth rates frequently estimated in the high teens to mid-20s percent. Key drivers include aging populations, the diabetes epidemic, rising surgical volumes, and growing demand in aesthetics, partly fueled by GLP-1 weight-loss medications. The sector spans profitable commercial leaders like Integra LifeSciences and Vericel to early-stage platform companies such as Conexeu Sciences, which began trading on Nasdaq in May 2026 with its collagen-based extracellular-matrix platform. Reimbursement policy and regulatory pathways remain critical risks, as illustrated by recent upheaval in the U.S. skin-substitute market affecting companies like Organogenesis and MiMedx.
MDXG ▼ORGO ▼IART ▲VCEL ▲CNXU ▲
Biotech & Genomic Medicine ▲Aging Population ▲
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering ▲Demand
Aging Population › Medical Devices for the Aging Body ▲Technology
Aging Population › Chronic-Disease Pharma Franchises Competition
MDXG · Regulation · Negative Recent upheaval in the U.S. skin-substitute market due to reimbursement and regulatory risks negatively affects MiMedx.
ORGO · Regulation · Negative Recent upheaval in the U.S. skin-substitute market due to reimbursement and regulatory risks negatively affects Organogenesis.
IART · Demand · Positive Mentioned as a profitable commercial leader benefiting from market growth driven by aging populations and rising surgical volumes.
VCEL · Demand · Positive Mentioned as a profitable commercial leader benefiting from market growth driven by aging populations and rising surgical volumes.
CNXU · Technology · Positive Early-stage platform company with collagen-based ECM platform, benefiting from sector growth and 3D bioprinting trends.
Read original ↗
GlobeNewswire·108dRead more →
© 2026 MarketDXAsset